KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2021 - 2025)

TherapeuticsMD's Liabilities from Discontinued Operations history spans 6 years, with the latest figure at 2667000.0 for Q4 2025.

  • For Q4 2025, Liabilities from Discontinued Operations fell 4.1% year-over-year to 2667000.0; the TTM value through Dec 2025 reached 2667000.0, down 4.1%, while the annual FY2025 figure was 2667000.0, 4.1% down from the prior year.
  • Liabilities from Discontinued Operations reached 2667000.0 in Q4 2025 per TXMD's latest filing, roughly flat from 2667000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 47911000.0 in Q4 2021 to a low of 1372000.0 in Q2 2023.
  • Average Liabilities from Discontinued Operations over 5 years is 7053785.71, with a median of 2854500.0 recorded in 2024.
  • Peak YoY movement for Liabilities from Discontinued Operations: crashed 84.62% in 2022, then skyrocketed 337.61% in 2024.
  • A 5-year view of Liabilities from Discontinued Operations shows it stood at 47911000.0 in 2021, then plummeted by 84.62% to 7369000.0 in 2022, then tumbled by 49.87% to 3694000.0 in 2023, then dropped by 24.72% to 2781000.0 in 2024, then dropped by 4.1% to 2667000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Liabilities from Discontinued Operations are 2667000.0 (Q4 2025), 2667000.0 (Q3 2025), and 2722000.0 (Q2 2025).